TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2155751
Drug: Subcutaneous calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous calcitonin (1, 10, 100 units)
Study: 7250475
Drug: Aromatic retinoid
Normalized name: Curcuma aromatica root oil
DrugBank: Curcuma aromatica root oil (DB11301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatic retinoid Ro 10-9359 (AR) combined with PUVA therapy (schedule C)
Study: 7250475
Drug: PUVA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA therapy alone
Study: 30488331
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (abstinence)
Study: 27692491
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - a handout on staying healthy during treatment
Study: 19671089
Drug: Tramadol Contramid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol Contramid OAD 200 mg
Study: 19671089
Drug: Tramadol Contramid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol Contramid OAD 300 mg
Study: 16281465
Drug: Prophylactic laser
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic laser treatment to the retina
Study: 31607823
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality (VR) sessions offered weekly (VRidays) and access to high-end VR stations in the Nexus Reality Lab.
Study: 17629752
Drug: Age, surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age, surgery type, platelets, body mass index, and length of time from surgery to chemotherapy
Study: 17371885
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy with tapered high-dose prednisone (group 3)
Study: 17405834
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy with infliximab (group 4)
Study: 17405834
Drug: Sequential monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential monotherapy (group 1)
Study: 18438829
Drug: Step-up combination
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-up combination therapy (group 2)
Study: 8201375
Drug: CYVADIC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYVADIC chemotherapy (cyclophosphamide 500 mg/m2 IV bolus on day 1, vincristine 1.4 mg/m2 IV bolus on day 1, doxorubicin 50 mg/m2 IV bolus on day 1, dacarbazine 400 mg/m2 by 1-hour infusion on days 1 to 3, repeated every 28 days for eight courses)
Study: 8201375
Drug: CYVADIC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYVADIC chemotherapy
Study: 3662061
Drug: midazolam 0.2
Normalized name: midazolam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 0.2 mg/kg
Study: 3662061
Drug: thiopental 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: thiopental 3.5 mg/kg
Study: 29549523
Drug: High cadence
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cadence (90 r/min) + taurine (50 mg/kg body mass)
Study: 29549523
Drug: High cadence
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cadence (90 r/min) + placebo (3 mg/kg body mass maltodextrin)
Study: 25867422
Drug: External rhGM‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: External rhGM‐CSF gel
Study: 25867422
Drug: rhGM‐CSF gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM‐CSF gel matrix components (Control)
Study: 21036772
Drug: Once-daily regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily regimen of emtricitabine, didanosine and efavirenz
Study: 21036772
Drug: Protease inhibitor‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor‐based regimen
Study: 16553634
Drug: Adjunctive metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive metronidazole plus amoxicillin
Study: 16553634
Drug: Adjunctive metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive metronidazole
Study: 15292323
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of GH therapy (0.35 U/kg.wk)
Study: 15292323
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of GH therapy
Study: 3874643
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg kg‐1 over 5 s
Study: 3874643
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg kg‐1 over 20 s
Study: 3874643
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg kg‐1 over 60 s
Study: 19487320
Drug: Gaboxadol (GBX)
Normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaboxadol (GBX) 5, 10, and 15 mg
Study: 19487320
Drug: Zolpidem (ZOL)
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolpidem (ZOL) 10 mg
Study: 16680965
Drug: MEBO treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEBO treatment
Study: 16680965
Drug: SD-Ag cream
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD-Ag cream treatment
Study: 10986219
Drug: L-ornithine-L-aspartate (LOLA)
Normalized name: ornithine, (L)-isomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine-L-aspartate (LOLA) 5 g intravenously
Study: 9380238
Drug: Dialysis patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis patients with elevated plasma silicon levels (3,849 and 2,350 micrograms/l)
Study: 31195867
Drug: Titrated oral
Normalized name: magnesium citrate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated oral solution of misoprostol
Study: 20691040
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (antibiotics, analgesics, and/or expectant management)
Study: 18941533
Drug: Ortho All‐Flex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ortho All‐Flex Diaphragm, lubricant gel (Replens) and condoms
Study: 18941533
Drug: Ortho All‐Flex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ortho All‐Flex Diaphragm, lubricant gel (Replens) and condoms with consistent use
Study: 16963850
Drug: Anecortave acetate
Normalized name: Anecortave acetate
DrugBank: Anecortave (DB12081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anecortave acetate 15 mg
Study: 12652226
Drug: Anecortave acetate
Normalized name: Anecortave acetate
DrugBank: Anecortave (DB12081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anecortave acetate (other doses)
Study: 7457415
Drug: Diltiazem 120,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120, 180, and 240 mg/day
Study: 6734694
Drug: metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 100 to 200 mg/day
Study: 6734694
Drug: oxprenolol 120
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oxprenolol 120 to 240 mg/day
Study: 24426817
Drug: Zolpidem-ER 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem-ER 12.5 mg (bedtime dosing)
Study: 24426817
Drug: Zaleplon 10
Normalized name: zaleplon 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaleplon 10 mg (middle-of-the-night dosing)
Study: 20003568
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g AXOS per day for 3 weeks
Study: 12741433
Drug: Fluconazole (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (800 mg loading dose, 200 or 400 mg daily maintenance dose depending on renal function)
Study: 11029368
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 400 microgram twice daily
Study: 1576648
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate 400 mg B.I.d for eight weeks
Study: 30971593
Drug: Terlipressin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin infusion at a dose of 2 μg/kg/h
Study: 30971593
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion at a dose of 0.1 μg/kg/min
Study: 18690353
Drug: Clopidogrel and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel and Aspirin
Study: 28460140
Drug: L-T4 treatment
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-T4 treatment
Study: 20636228
Drug: Sodium-restricted diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium-restricted diet (2-3 g/day) and fluid restriction (1.5 L/day)
Study: 18304952
Drug: Captopril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (2 mg/kg/day, three doses a day)
Study: 18304952
Drug: Nifedipine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (0.5 mg/kg/day, three doses a day)
Study: 15677832
Drug: Medium-guidance group
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-guidance group (MG; one supervised group session and two unsupervised home sessions per week, n = 16)
Study: 11860948
Drug: Immunization with
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunization with HFRS vaccine
Study: 8970471
Drug: Prophylactic HIV-1
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic HIV-1 vaccine
Study: 1622173
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg orally every 8 h for the first 72 h and then every 12 h for a total of 10 days) plus a beta‐lactam agent plus an aminoglycoside
Study: 1622173
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy of a beta‐lactam plus an aminoglycoside agent
Study: 6519163
Drug: Propranolol 120
Normalized name: propranolol 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 120 mg orally
Study: 28655079
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy only (CT)
Study: 8857476
Drug: Poloxamer-188 infusion
Normalized name: POLOXAMER 188
DrugBank: Poloxamer 188 (DB11333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poloxamer-188 infusion for 48 hours
Study: 8857476
Drug: Poloxamer-188 infusion
Normalized name: POLOXAMER 188
DrugBank: Poloxamer 188 (DB11333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poloxamer-188 infusion
Study: 1346790
Drug: D1 agonist,
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1 agonist, piribedil, at 50‐100 mg/day, orally, for 8 weeks
Study: 1346790
Drug: D2 agonist,
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2 agonist, bromocriptine, at 2.5 ‐ 5 mg/day, orally, for another 8 weeks
Study: 6206718
Drug: Transfusion group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion group (hemoglobin level kept above 10.0 g/dL)
Study: 24231216
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg/d), tamsulosin (0.4 mg/d), saw palmetto (320 mg/d)
Study: 24231216
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg/d), saw palmetto (320 mg/d)
Study: 18435852
Drug: Rosiglitazone added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone added to metformin
Study: 22953318
Drug: Metformin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin with family-based behavioural weight loss programme
Study: 17538890
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (PnCRM7)
Study: 17538890
Drug: 3-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose regimen for those 7-11 months of age
Study: 17538890
Drug: 2-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose regimen for those 12-23 months of age
Study: 15037536
Drug: Infliximab (anti-TNF-alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (anti-TNF-alpha therapy)
Study: 15037536
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment in combination with infliximab
Study: 11813591
Drug: ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine bismuth citrate b.i.d. co-prescribed with clarithromycin 250 mg q.i.d.
Study: 11813591
Drug: ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine bismuth citrate b.i.d. co-prescribed with clarithromycin 500 mg b.i.d.
Study: 11813591
Drug: ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine bismuth citrate b.i.d. co-prescribed with clarithromycin 500 mg b.i.d. plus metronidazole 400 mg b.i.d.
Study: 11813591
Drug: ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine bismuth citrate 400 mg b.i.d. for 14 days after initial treatment
Study: 9726701
Drug: Jet injection
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet injection of midazolam at doses of 100, 150, and 200 microg/kg
Study: 9726701
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) injection of midazolam at a dose of 80 microg/kg
Study: 9726701
Drug: Jet injection
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet injection of midazolam at 200 microg/kg
Study: 9726701
Drug: Jet injection
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet injection of midazolam
Study: 9726701
Drug: Jet injection
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet injection and i.m. injection of midazolam
Study: 9073056
Drug: Doxorubicin (A)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (A) 40 mg/m2 + Melphalan (M) 0.4 mg/kg + Cisplatin (C) 50 mg/m2
Study: 9073056
Drug: Doxorubicin (A)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (A) 40 mg/m2 + Melphalan (M) 0.4 mg/kg
Study: 26797134
Drug: Active beverage
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active beverage containing 361 mg of (poly)phenols and 120 mg of vitamin C, taken twice daily for 4 weeks
Study: 24362012
Drug: Hydration group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration group (increased water intake by 1.0-1.5 L/day for 6 weeks)
Study: 21598839
Drug: Hypnosis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis with post-hypnotic suggestion
Study: 19854321
Drug: Systemic corticosteroids
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic corticosteroids (prednisone 50-100 mg equivalent)
Study: 19854321
Drug: Nontapered 5-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nontapered 5- to 10-day course of corticosteroid therapy
Study: 19854321
Drug: Combinations of
Normalized name: Combinations of vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combinations of oral and inhaled corticosteroids
Study: 19854321
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and intravenous corticosteroids, intramuscular and oral corticosteroid regimens
Study: 19854321
Drug: Corticosteroid doses
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid doses greater than standard doses
Study: 15568599
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion (10 microg/kg/min for 72 hours)
Study: 15568599
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (digitalis, diuretics, ACE-inhibitors)
Study: 11737815
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream (petrolatum)
Study: 9357454
Drug: PTA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTA plus medical treatment
Study: 9357454
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment alone (control group)
Study: 1337161
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol (0.5 micrograms/day) for 8 weeks
Study: 24398786
Drug: Freeze-dried powdered
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried powdered yacon (FDY) containing 7.4 g of FOS
Study: 19846793
Drug: Metformin and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and/or Insulin
Study: 17902730
Drug: 5% minoxidil
Normalized name: MINOXIDIL 5 g in 100 mL TOPICAL LIQUID [ASDTOTIO 5% minoxidil]
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% minoxidil applied twice daily
Study: 17902730
Drug: Combined 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 5% minoxidil and 0.01% tretinoin applied once daily at night
Study: 16234763
Drug: Nebivolol (5-7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5-7.5 mg/day)
Study: 16234763
Drug: Atenolol (75-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (75-100 mg/day)
Study: 10101621
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose dynorphin A(1-13) (500 micrograms/kg)
Study: 10101621
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose dynorphin A(1-13) (120 micrograms/kg)
Study: 7771420
Drug: Antireflux therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antireflux therapy (three types: two medical therapies and one surgical therapy)
Study: 2342006
Drug: Cefotetan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (2 g intravenously with induction of anaesthesia)
Study: 2342006
Drug: Piperacillin (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (three doses of 2 g)
Study: 6242956
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg mane
Study: 6242956
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg nocte
Study: 19355844
Drug: Cholinesterase inhibitor
Normalized name: Acetylcholinesterase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitor (ChEI) treatment for 20 weeks
Study: 14739496
Drug: roxithromycin (ROM)
Normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin (ROM) 2x150 mg/day orally for 4 weeks
Study: 14739496
Drug: placebo 2x1
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 2x1 tablet/day for 4 weeks
Study: 11552198
Drug: Calf muscles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calf muscles stretching (control treatment)
Study: 9972406
Drug: Liposomal encapsulated
Normalized name: liposomal encapsulated paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liposomal encapsulated doxorubicin (DOX‐SL) 20‐40mg/m2 administered by intravenous infusion over 30‐60 minutes every two weeks
Study: 3130890
Drug: Atropine 1
Normalized name: homatropine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 1 mg
Study: 14987305
Drug: Mequitazine 5
Normalized name: mequitazine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mequitazine 5 mg
Study: 31018832
Drug: Aggregate treatment
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggregate treatment effect estimates
Study: 20390429
Drug: Zibotentan (ZD4054)
Normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zibotentan (ZD4054) 10 mg or 15 mg
Study: 12827121
Drug: Topical local
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical local anesthetic (adrenaline 1:1,000, lignocaine 4%, amethocaine 0.5%)
Study: 12827121
Drug: Placebo (adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (adrenaline 1:1,000 solution)
Study: 8894262
Drug: Quinapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (10 mg, doubled to 40 mg in nonresponders)
Study: 8894262
Drug: Metoprolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50 mg, doubled to 200 mg in nonresponders)
Study: 8894262
Drug: Quinapril (52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (52 weeks treatment in a volunteer group of 327 patients)
Study: 8894262
Drug: Metoprolol (52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (52 weeks treatment in a volunteer group of 327 patients)
Study: 30616662
Drug: MATCH (Modular
Approvals — FDA: no, EMA: no, PMDA: no
Description: MATCH (Modular Approach to Therapy for children with Anxiety, Depression, Trauma and Conduct problems)
Study: 22967497
Drug: Antazoline administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antazoline administered intravenously in divided doses
Study: 22967497
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously in divided doses
Study: 19631852
Drug: Indirect pulp
Normalized name: acai fruit pulp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect pulp capping treatment; specific details on dosage and duration not available.
Study: 28781129
Drug: IH oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IH oxytocin (all doses)
Study: 23760428
Drug: Escitalopram (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (selective serotonin reuptake inhibitor)
Study: 18053020
Drug: Triflusal (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal (225 mg, 450 mg, 900 mg)
Study: 12671885
Drug: Fructooligosaccharides (FOS)
Normalized name: fructooligosaccharides (FOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructooligosaccharides (FOS) 6.6 g, administered 3 times daily after meals